Influence of the 5-HT2C receptor antagonist SB242,084 on behaviour produced by the 5-HT2 agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine

1 Ro60-0175 has been described as a selective agonist at the 5-HT2C receptor, yet it has only 10-fold higher affinity at the 5-HT2C compared to the 5-HT2A subtype, and equivalent affinity for the 5-HT2B receptor. 2 The selective 5-HT2C receptor antagonist SB242,084 (0.5 mg kg(-1) i.p.), blocked the hypoactivity and penile grooming induced by Ro60-0175 (1 mg kg(-1) s.c.). The combination of SB242,084 (0.5 mg kg(-1) i.p.) and Ro60-0175 (3-10 mg kg(-1)) produced a completely different pattern of behaviours including wet-dog shakes, hyperactivity and back muscle contractions. These latter effects were blocked by the selective 5-HT2A receptor antagonist MDL100,907 (0.5 mg kg (1) i.p.), but not the 5-HT2B receptor antagonist SB215,505 (3 mg kg (1) p.o.). 3 The indirect 5-HT releaser/reuptake inhibitor dexfenfluramine (1-10 mg kg (1) i.p.) produced a mild increase in locomotor activity, penile grooming, and occasional back muscle contractions and wet-dog shakes. Pre-treatment with SB242,084 (0.5 mg kg(-1)), blocked the incidence of penile grooming, and markedly potentiated both the dexfenfluramine-induced hyperactivity, the incidence of back muscle contractions, and to a lesser extent wet-dog shakes. Some toxicity was also evident in animals treated with dexfenfluramine (10 mg kg(-1))/SB242.084 (0.5 mg kg (1)), but not in any other treatment groups. 4 The hyperactivity and toxicity produced by the dexfenfluramine (10 mg kg(-1))/SB242,084 (0.5 mg kg(-1)) combination was replicated in a further study, and hyperthermia was also recorded. Both hyperthermia and toxicity were blocked by MDL100,907 (0.5 mg kg(-1)) but not SB215,505 (3 mg kg(-1)). An attenuation of the hyperlocomotor response was also observed following MDL100,907. 5 These findings suggest that 5-HT2C receptor activation can inhibit the expression of behaviours mediated through other 5-HT receptor subtypes.